Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. Issue 5 (16th April 2019)

• Record Type: Journal Article
• Authors: Moleti, Maria Luisa; Al-Jadiry, Mazin Faisal; Shateh, Wafa Ablahad; Al-Darraji, Amir Fadhil; Mohamed, Sara; Uccini, Stefania; Piciocchi, Alfonso; Foà, Robin; Testi, Anna Maria; Al-Hadad, Salma
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 5(2019)
• Page Start: 1224
• Page End: 1233
• Publication Date: 2019-04-16
• Subjects: B-cell non-Hodgkin lymphoma -- children -- low-income country; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1519810
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Since 2000, an adapted LMB 96 protocol was implemented at the Children-Welfare-Teaching-Hospital in Baghdad for the treatment of childhood B-cell non-Hodgkin lymphoma. The first experience (2000–2005) demonstrated efficacy and feasibility of this protocol in Iraq. In 2006, further adjustments were made in an attempt to reduce therapy-related toxicities. The outcome of the second cohort of 190 children (2006–2010) and the comparison with the previous study are hereby reported. Out of the 180 treated patients, 120 achieved a complete response; during treatment 51 died and 9 abandoned. The 60-month overall survival (OS) and event-free survival (EFS) were 64.7 and 56.3%, respectively. No differences were observed in the 24-month OS and EFS between the 2000–2005 and 2006–2010 cohorts (66.3% vs. 65.1%; p = .89 and 53.3% vs. 57.3%; p = .28, respectively). Therapeutic group-B in the second cohort showed better outcome, although not significant, compared to the first one (EFS 62.9% vs. 53.8%; p = .088). Therapy-related mortality remained high.